Sun Pharma Q4 Results: Net Profit Falls 19% to Rs 2,153.9 Crore, Revenue Up 8.5%; Final Dividend Announced

Sun Pharma Q4 Results 2025: Sun Pharmaceutical Industries Ltd, India's largest pharmaceutical company by market capitalisation, on Thursday announced its financial results for the fourth quarter (Q4) and the full year ending 31 March 2025. The company reported a mixed performance, marked by robust revenue growth but a notable dip in net profit for the quarter.

Sun Pharma Q4 Results 2025: Cons PAT Fall, Revenue Up, Dividend Announced

For the quarter ended 31 March 2025, Sun Pharma's consolidated net profit dropped by 19% year-on-year (YoY) to Rs 2,153.9 crore, compared to Rs 2,658.74 crore in the same period last year. However, revenue from operations rose by 8.49% YoY, reaching Rs 12,815.58 crore, up from Rs 11,813.33 crore in Q4FY24.

Gross sales for the quarter stood at Rs 12,815.6 crore, with India formulation sales contributing Rs 4,213 crore, representing a 13.6% YoY increase. The growth in the domestic market was driven by continued momentum in chronic and speciality segments.

Sun Pharma Final Dividend Declaration: Pharma Stock Dividend

The company's Board of Directors has recommended a final dividend of Rs 5.5 per equity share of face value Rs 1 each. The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM). The record date for eligible shareholders is Monday, 7 July 2025, and if approved, the dividend will be paid on or before Friday, 8 August 2025.

Sun Pharma Global Sales in Q4 FY2025

Sun Pharma's global speciality business continued to show strength, with specialty sales reaching $295 million in Q4FY25, an 8.6% increase YoY, contributing 19.9% to the total quarterly revenue.

• Emerging Market (EM) formulation sales came in at $261 million, up 6.3% YoY.
• Rest of World (RoW) formulation sales stood at $200 million, marking a 2% YoY growth.

In the United States (US), the company's largest overseas market, formulation sales fell 2.5% YoY to $464 million in Q4, though full-year performance remained positive.

Sun Pharma Operational & Financial Metrics

The company recorded Research and Development (R&D) expenses of Rs 816.6 crore during the quarter, underlining its continued investment in innovation and product pipeline expansion.

Sun Pharma posted EBITDA of Rs 3,716.1 crore in Q4FY25 including other operating income, representing a 22.4% YoY growth, with an EBITDA margin of 28.7%.

Adjusted net profit, excluding exceptional items, stood at Rs 2,889.1 crore, showing a 4.8% increase YoY, indicating an underlying improvement in operational efficiency.

Sun Pharmaceutical Full-Year FY25 Performance

The global major pharma company reported strong growth in its domestic business for the full financial year 2024-25. India formulation sales totalled Rs 16,923 crore, registering a 13.7% year-on-year (YoY) increase, driven by continued momentum in chronic therapies and a robust branded generics portfolio.

In the United States, Sun Pharma's largest export market, formulation sales for FY25 reached $1,921 million, reflecting a 3.6% YoY growth. This was achieved despite a softer performance in the fourth quarter, underlining the company's resilience in a challenging regulatory and competitive landscape.

Global specialty sales rose 17.1% YoY to $1,216 million, supported by expanding penetration of key products such as Ilumya and Cequa. EM formulation sales stood at $1,114 million for the year, marking a 7% increase YoY. Meanwhile, the Rest of World (RoW) markets contributed $847 million, showing a 4.5% rise YoY.

API Segment Performance

The Active Pharmaceutical Ingredients (API) business also delivered strong results. For Q4FY25, external API sales surged 28.2% YoY to Rs 533 crore, reflecting heightened demand and operational efficiency. On a full-year basis, FY25 API revenue reached Rs 2,129 crore, representing an 11% YoY increase.

The company noted that its API portfolio continues to support both internal formulation needs and external supply to customers globally.

Sun Pharma Share Price Today

As of the market close on 22 May 2025, Sun Pharmaceutical Industries Ltd ended the trading session at Rs 1,724.70, marking a decline of Rs 7.10 or 0.41% from the previous day's close. The stock opened the day at Rs 1,734.20, touched an intraday high of Rs 1,740.00, and hit a low of Rs 1,707.20 during the session.